Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Diagnostic Cytopathology|June 22, 2022
Diagnostic utility of flow cytometry in identifying histiocytic sarcoma-A case reportPritika Kushwaha, Meeta Singh, Sneha Datwani, et al.
Human Pathology|May 29, 2025
Artificial intelligence in breast pathology: Overview and recent updatesSneha Datwani, Hikmat Khan, Muhammad Khalid Khan Niazi, et al.
Pathogens & Immunity|November 30, 2023
Dynamics of T-cell Responses Following COVID-19 mRNA Vaccination and Breakthrough Infection in Older AdultsSneha Datwani, Rebecca Kalikawe, Francis Mwimanzi, et al.
Open Forum Infectious Diseases|March 13, 2023
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA VaccineFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
Viruses|May 25, 2024
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral TherapySneha Datwani, Rebecca Kalikawe, Rachel Waterworth, et al.
Frontiers in Immunology|September 23, 2022
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccinationHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
The Journal of Infectious Diseases|May 11, 2022
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Pageof 2